公开(公告)号：EP3712260A1

公开(公告)日：2020-09-23

申请号：EP18877609.0

申请日：2018-11-13

申请人： Guangzhou Institute Of Biomedicine And Health, Chinese Academy Of Sciences

发明人： LI, Yi ,  ZHOU, Peipei

IPC分类号： C12N5/22 ,  A61K39/00 ,  A61P31/00 ,  A61P35/00

摘要： Provided is a genetically engineered γδT cell, which is characterized in that a high-affinity αβTCR gene is transferred into the γδT cell, and the affinity of the high-affinity αβTCR to the specific pMHC thereof is at least two times of that of a wild-type αβTCR corresponding thereto. Further provided are a use of and a preparation method for the γδT cell.

公开(公告)号：EP3702459A1

公开(公告)日：2020-09-02

申请号：EP18870546.1

申请日：2018-10-26

申请人： Edigene Inc.

发明人： YUAN, Pengfei ,  FANG, Riguo ,  YU, Lingling ,  XIA, Penghui ,  WANG, Jia ,  LIANG, Fucai

IPC分类号： C12N15/113 ,  C12N5/22 ,  C12N9/22 ,  A61K35/18 ,  A61P7/06

摘要： Provided is a method for genetically editing an enhancer locus of hematopoietic stem cell BCL11A, comprising: disrupting the CTTCCT region of a BCL11A genome by gene editing technology. The genetically edited hematopoietic stem cells have normal cell functions and can significantly increase the expression of fetal hemoglobin, thereby being used for the treatment of β thalassemia and sickle cell anemia.

公开(公告)号：EP3694561A1

公开(公告)日：2020-08-19

申请号：EP18866878.4

申请日：2018-10-12

申请人： Mayo Foundation for Medical Education and Research

发明人： CHANG, Xiu-Bao

IPC分类号： A61K48/00 ,  A61P3/00 ,  A61P35/00 ,  C07H21/02 ,  C07K19/00 ,  C12N5/16 ,  C12N5/22

公开(公告)号：EP3071686B1

公开(公告)日：2020-07-22

申请号：EP14802421.9

申请日：2014-11-21

申请人： Cellectis SA

发明人： SOURDIVE, David ,  DESSEAUX, Carole ,  SCHARENBERG, Andrew

IPC分类号： C12N5/0783 ,  C12N5/22 ,  A61K35/14 ,  C12N5/16 ,  A61K35/17

公开(公告)号：EP3578643A1

公开(公告)日：2019-12-11

申请号：EP19175179.1

申请日：2015-03-26

申请人： The Salk Institute for Biological Studies

发明人： EVANS, Ronald, M. ,  YOSHIHARA, Eiji ,  DOWNES, Michael, R. ,  YU, Ruth, T. ,  ATKINS, Annette, R.

IPC分类号： C12N5/10 ,  C12N5/074 ,  C12N5/22 ,  A61K35/39

摘要： The invention features compositions comprising in vitro generated beta cells capable of glucose-stimulated insulin secretion, methods of inducing beta cell maturation from embryonic or induced pluripotent stem cell-derived beta-like cells, and methods of using in vitro generated beta cells for treatment of type 1 diabetes, type 2 diabetes, or a related disorder.

公开(公告)号：EP3411079A1

公开(公告)日：2018-12-12

申请号：EP17746953.3

申请日：2017-01-26

申请人： Nanjing Legend Biotech Co., Ltd.

发明人： FAN, Xiaohu ,  ZHANG, Fangliang ,  ZHUANG, Qiuchuan ,  WANG, Pingyan ,  YU, Jie ,  HE, Xian ,  WANG, Lin ,  HAO, Jiaying ,  YANG, Lei

IPC分类号： A61K48/00 ,  C12N5/16 ,  C12N5/22 ,  A61P35/00

CPC分类号： C12N5/0636 ,  A61K35/17 ,  A61K39/0011 ,  A61K2039/505 ,  A61K2039/507 ,  A61K2039/5156 ,  A61K2039/5158 ,  A61K2039/572 ,  C07K16/00 ,  C07K16/2818 ,  C07K16/2863 ,  C07K16/32 ,  C07K2317/73 ,  C12N5/16 ,  C12N2501/48 ,  C12N2501/51 ,  C12N2510/02 ,  C12N2740/16043

摘要： Provided are pharmaceutical compositions comprising an engineered mammalian cell comprising a heterologous nucleic acid encoding an immunomodulator. Further provided are methods of treating cancer using the pharmaceutical composition either singly or in combination with other technologies, such as Chimeric Antigen Receptor (CAR) or recombinant T cell receptor (TCR) modified T cell immunotherapy.

公开(公告)号：EP1723972B1

公开(公告)日：2018-01-24

申请号：EP06290796.9

申请日：2006-05-16

申请人： L'Oréal

发明人： Collin-Djangone, Christine ,  Simonnet, Jean-Thierry

IPC分类号： C12N5/22 ,  A61K49/00

CPC分类号： A61K49/0006 ,  A61K9/1075 ,  A61K9/1272 ,  A61K9/5153 ,  A61K31/713 ,  C12N5/0698

公开(公告)号：EP3027739A1

公开(公告)日：2016-06-08

申请号：EP14842923.6

申请日：2014-09-04

申请人： Shanghai Sidansai Biotechnology Co., Ltd

发明人： ZHAO, Wu

IPC分类号： C12N5/16 ,  C12N5/22 ,  C12N5/0735 ,  C12N5/074 ,  C12N5/0789

CPC分类号： C12N5/0647 ,  A61K35/14 ,  C12N5/0641 ,  C12N2506/02 ,  C12N2510/00

摘要： A genetically modified cell (e.g., stem cell) containing a complete or partial gene deletion of one or more genes of a blood group antigen (BGA) biosynthesis or transportation pathway is provided. The systems and methods provided herein facilitate the generation of blood substitutes (e.g., blood cells).

公开(公告)号：EP2989464A1

公开(公告)日：2016-03-02

申请号：EP14787491.1

申请日：2014-04-23

申请人： Chromocell Corporation

发明人： RADHAKRISHNA, Harish ,  JENKINS, Maya ,  ANOBILE, Jonathan

IPC分类号： G01N33/566 ,  C12N5/22

CPC分类号： G01N33/502 ,  G01N33/566

摘要： The present invention is based on applicants' discovery, disclosed herein, of agonists for the TAS2R receptors TAS2R1, TAS2R4, TAS2R9, TAS2R13, TAS2R14, TAS2R16, TAS2R38, TAS2R39, TAS2R44, TAS2R46, and TAS2R60. The assignment of agonists to these receptors makes assays for identifying compounds that modulate bitter taste possible. For example, the present invention provides methods of identifying compounds that inhibit the bitter taste due to these agonists. The present invention also provides methods of identifying compounds that selectively inhibit the bitter taste due to these agonists. The present invention further provides methods of identifying compounds that mimic the bitter taste due these agonists. The present invention also provides methods of identifying compounds that enhance the bitter taste due to these agonists.

公开(公告)号：EP2962113A1

公开(公告)日：2016-01-06

申请号：EP14756627.7

申请日：2014-02-28

申请人： Biocare Medical, LLC

发明人： TACHA, David ,  QI, Weimin

IPC分类号： G01N33/574 ,  C12N5/16 ,  C12N5/22 ,  C07K16/28

CPC分类号： C07K16/18 ,  C07K16/28 ,  C07K16/32 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/34 ,  C07K2317/565 ,  G01N33/5017 ,  G01N33/574 ,  G01N33/57423 ,  G01N33/57484 ,  G01N33/57488 ,  G01N33/577

摘要： The present invention is related to the anti-p40 antibodies, kits, cocktails, and use of anti-p40 antibodies for detection of cancer.

摘要翻译： 本发明涉及用于检测癌症的抗p40抗体，试剂盒，鸡尾酒和抗p40抗体。